Franklin Covey

FC

Market cap $267M

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the use of LINZESS® (linaclotide) in pediatric patients 2 years of age and older with functional constipation (FC). LINZESS was previously approved for pediatric patients 6 years and older with FC. With thi.

SALT LAKE CITY--(BUSINESS WIRE)-- #AI--As organizations race to capture the benefits of artificial intelligence, research from FranklinCovey Institute reveals a critical obstacle: most employees feel they are navigating AI alone, without meaningful support or guidance. Eighty percent of individual contributors describe their manager's approach to AI as “hands-off,” which underscores a widening gap between AI's potential and how it's actually used at work. FranklinCovey's 2025 AI General Attitudes Sur.

Diploma LON: DPLM reported what management described as a “very strong” first half for the six months ended March 31, 2026, with double-digit organic growth, higher margins and upgraded full-year expectations.

TORONTO, May 05, 2026 (GLOBE NEWSWIRE) -- Firm Capital Mortgage Investment Corporation (the “Corporation”) (TSX FC, FC.DB. K, FC.DB. L and FC.DB.M) today released its financial statements for the three months ended March 31, 2026.

As of April 2, 2026, two stocks in the industrials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Franklin Covey Co. (FC) Q2 2026 Earnings Call Transcript

Franklin Covey (FC) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of breakeven. This compares to a loss of $0.08 per share a year ago.

SALT LAKE CITY--(BUSINESS WIRE)--Franklin Covey Co. (NYSE: FC), a global leadership and organizational performance partner, gives strategy the human edge. We help clients achieve breakthrough results and transform how they execute strategy at scale. Today, the Company announced its financial results for the second quarter of fiscal 2026, which ended on February 28, 2026. Second Quarter Fiscal 2026 Financial Overview The Company's consolidated revenue for Q2 FY2026 was $59.6 million, which was f.

SALT LAKE CITY--(BUSINESS WIRE)-- #CNO--FranklinCovey Provides Customized Solutions for Healthcare Organizations to Solve Key Issues: Nurse Retention and Patient Satisfaction.

Despite the recent fundamental declines, I believe Franklin Covey remains structurally attractive with material untapped TAM despite that should prevail past recent weakness. I'll be watching for continued sales momentum as reflected in Q1, continued new logo growth generation, SG&A levels, guidance, and capital allocation (particularly share repurchases). Despite the price run-up in recent weeks, I still believe FC offers an attractive IRR.